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Severe infections result in significant morbidity and 
mortality. An infection can be considered severe if: (1) 
the responsible bacteria are multiresistant or difficult to 
treat; (2) the infection involves bacteremia, pneumonia 
or complicated intra-abdominal infections or urinary 
tract infections; (3) patients are neutropenic or other- 
wise immunocompromised with ultimately or rapidly 
fatal underlying illness; (4) there is septic shock; and 
(5) the severity score is high, especially in intensive care 
unit (ICU) patients. In severe infections, antibiotic 
therapy must be administered promptly for maximal 
efficacy. The results of the cultures become available 
afterwards, making the choice of empirical therapy 
critically important for the prognosis. Successful anti- 
microbial regimens for severe infections include 
p-lactam/p-lactamase inhibitor combinations, third- 
generation cephalosporins, aminoglycosides, or fluoro- 
quinolones, alone or in combination. 
Cefepime, an amino-2-thiazolyl oxy-iminocephalo- 
sporin, is zwitterionic. Its antibacterial spectrum 
includes Gram-negative pathogens susceptible or 
resistant to ceftazidime. Furthermore, cefepime is as 
active as cefotaxime against Gram-positive cocci, 
including pneumococci with reduced susceptibility to 
penicillin [l-41. Cefepime differs from third-genera- 
tion cephalosporins in its kinetics of penetration 
through the bacterial wall of enterobacteria, its low 
affinity for cephalosporinases, and its specific affinity 
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for penicillin-binding proteins [5,6]. In vitro and in 
vivo studies have shown that cefepime is less prone than 
other cephalosporins to select resistant strains [7,8]. 
Cefepime, alone or combined with other anti- 
biotics like aminoglycosides, metronidazole or glyco- 
peptides, has already proved its efficacy and safety in the 
treatment of different, severe bacterial infections, such 
as complicated intra-abdominal infection, ventilator- 
associated pneumonia (VAP) in ICU patients, and 
febrile neutropenic patients. The objective of this paper 
is to synthesize the results of the major published studies 
where cefepime has been evaluated in the treatment of 
severe bacterial infections. 
CLINICAL ACTIVITY OF CEFEPIME IN SEVERE 
BACTERIAL INFECTIONS AND SEPSIS 
Kieft et a1 [9] compared the clinical efficacy of 
intravenous cefepime (2 g twice-daily) in 69 patients 
and intravenous ceftazidime (2 g three times a day) 
in 64 patients in the treatment of severe bacterial 
infections and sepsis. The two groups were similar 
according to their clinical, epidemiologic and bacterio- 
logic characteristics, but data concerning ICU patients, 
especially patients with mechanical ventilation, are 
missing, as is the number of patients with nosocomial 
infections (Table 1). The severity of the infections was 
questionable: the APACHE I1 score value was relatively 
low in the two groups; no patient presented with septic 
shock; urinary tract infections were the most frequent 
infections; the microbiological data were in accordance 
with community-acquired infections, with very few 
isolates of Pseudomonas sp. Finally, both cefepime and 
ceftazidime had the same favorable clinical outcome in 
intent-to-treat (79% versus 81%) or per protocol (90% 
versus 87%) analysis. The bacteriologic eradication 
rate was 78% versus 70%. The high rate of favorable 
outcome confirmed the relatively low severity of the 
treated infections. 
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Table 1 Clinical evaluation of cefepime compared to 
ceftazidime in severe bacterial infections and sepsis 191 
Cefepime Ceftazidime 
(n=69) (n=64) 
Patient characteristics 
Evaluable patients (n) 
APACHE I1 score 
Septic shock (ti) 
Mechanical ventilation (n) 
Nosocomial infections (n) 
Bacteremia (n) 
Respiratory tract infections (n) 
Complicated urinary tract 
Microbiologically documented 
Polymicrobial infections (n) 
infections (?I)  
infections (n) 
Bacteriologic data 
Gram-positive bacteria 
Staphylococcus aureus 
Streptococcus pneumoniae 
Enterococcus faecafis 
Gram-negative bacteria 
Enterobacteriaceae 
Pseudomonas sp. 
Favorable clinical and bacteriologic 
response 
Clinical outcome rate (96) 
Intent-to-treat analysis 
Per protocol analysis 
Eradication 
Bacteriologic outcome rate (%) 
56 58 
17 16 
0 0 
N D  N D  
N D  N D  
7 7 
11 7 
15 19 
30 31 
8 3 
17 9 
4 1 
6 5 
2 2 
22 31 
19 26 
0 3 
79 81 
90 87 
78 70 
A French multicenter open, non-comparative 
study [ lo ]  evaluated the clinical and bacteriologic 
efficacy of intravenous cefepime (2 g twice-daily) in the 
treatment of severe infections in 502 patients hospita- 
lized in ICUs (73%) or infectious diseases units (27%). 
Their mean age was 6 0 f 1 8  years, and the mean 
Simplified Acute Physiological Score I (SAPS I) was 
11 .8  f4 .9 .  The main infections were pneumonia 
(n=338) ,  upper urinary tract infections (n=101),  and 
bacteremia (n= l16) .  Thirty patients presented with 
sepsis without detectable bacteremia or primary 
localization. The infections were hospital-acquired in 
291 cases (58%). Prior ineffective antibiotic therapy had 
been prescribed in 227 patients. Four hundred and 
eighty-five pathogens were isolated in 3 4 6  patients 
(69%), from blood cultures (n=71),  respiratory samples 
(sputum, protected distal brushing or bronchoalveolar 
lavage) (n=286)  and urinary samples (nx114) .  The 
most frequently isolated pathogens were Entero- 
bacteriaceae (n=229) ,  Pseudomonas aeruginosa (n =67), 
Streptococcus pneumoniae (n =45),  Staphylococcus aureus 
(n=44)  and Haemophilus infuenzae (n=31) .  Fifty-four 
Enterobacteriaceae isolates produced inducible cephalo- 
sporinase: Enterobacter sp. (n=31),  Protens spp. (n=12),  
Serratia sp. (n=7) and Citrobacterjeundii (n=4). Cefepime 
was used as monotherapy in 199 patients or in com- 
bination in 303 patients, with a mean treatment 
duration of 9 f 3 days. One hundred and twenty-seven 
patients were excluded from the per protocol analysis 
because of the use of prior effective antibiotic therapy 
in the 48 h before inclusion (n=50) ,  treatment duration 
shorter than 5 days (n=50) ,  or primary resistance in 
18 pathogens (Acinetobacter baumanii = 7, methicillin- 
resistant Staphylococcus aureus = 5, Pseudomonas aeruginosa 
=6) .  Seventy-three per cent (336/502) of the patients 
were cured in intent-to-treat analysis, and 86% (322/ 
375) in per protocol analysis (Table 2). Bacteriologic 
eradication in per protocol analysis was obtained in 253 
of263 (96%) patients, in 149 of 159 (94%) patients with 
pneumonia, in 83 of 83 (100%) with urinary tract 
infection and in 25 of 25 (100%) with bacteremia. All 
strains of Enterobacteriaceae were susceptible (MIC < 4 
mg/L, 99%) or intermediate (1%) to cefepime. The 
MICsos and MIC90s of Enterobacteriaceae were 0 .03  
and 0.12 mg/L for cefepime, 0.06 and 0.5 mg/L for 
cefotaxime, and 0.12 and 0.5 mg/L for ceftazidime. 
Sixty-nine per cent and 31% of Pseudomona aeruginosa 
strains were respectively susceptible or intermediate to 
cefepime. The MICsos and MICms of Pseudomonas 
aeruginosa were 2 and 16 mg/L for cefepime and 1 and 
4 mg/L for ceftazidime. The correlation of the MICs 
of 226 strains with the clinical outcome in per protocol 
Table 2 Clinical evaluation of cefepime in severe bacterial infections and sepsis [lo] 
Clinical cure (“Yo) 
Pneumonia Urinary tract infections Sepsis 
ITTd PPb ITT PP ITT PP 
Community-acquired infections 76 86 96 97 77 92 
Nosocomial infections 63 80 88 95 61 82 
Total 68 82 94 97 69 88 
‘Intent-to-treat analysis; bper protocol analysis. 
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analysis showed that the clinical failures were mostly 
related to Pseudomonas aeruginosa, Pseudomonas cepacia, 
followed by Enterobacter sp., Serratia sp. and C. j eund i i ,  
in the most severe nosocomial infections. Eleven patients 
were infected with Enterobacteriaceae susceptible to 
cefepime, but resistant to cefotaxime; all these patients 
were clinically cured, with bacteriologic eradication 
with cefepime alone in five cases, or in combination in 
six cases. 
In these two studies, cefepime has shown its high 
efficacy in the empirical treatment of severe infections, 
and its in vitro efficacy on third-generation cephalo- 
sporin-resistant strains has been confirmed. 
CLINICAL ACTIVITY OF CEFEPIME IN NOSOCOMIAL 
PNEUMONIA IN ICUs 
Among nosocomial infections, pulmonary infections 
rank third in incidence for all hospitalized patients and 
first for patients in ICUs. Invasion of the pulmonary 
parenchyma by nosocomial bacteria results in a 35- 
60% mortality rate. The causative pathogens are usually 
pneumococci or H. inzuenzae in early-onset pneumonia, 
and Staphylococcus aureus and Pseudomonas aeruginosa in 
late-onset pneumonia. Multiresistant bacteria are often 
involved in these infections. At present, the choice of 
treatment for nosocomial pneumonia and especially for 
VAP is most often a broad-spectrum antibiotic with 
rapid bactericidal activity. Two studies concerning 
cefepime have been conducted in ICU patients with 
very severe infections and poor underlying conditions. 
Gouin et a1 [ l l ]  have evaluated, in a French 
multicenter non-comparative prospective study, the 
effectiveness of intravenous cefepime (2 g twice-daily) 
in combination with intravenous amikacin (7.5 mg/kg 
twice-daily) in the treatment of severe bacterial 
infections in 118 ICU patients, including 113 patients 
(mean age 51 years) with nosocomial lower respiratory 
tract infections. Ninety-six per cent (108/113) of the 
patients required ventilation and 12% (14/113) had 
associated bacteremia. Eighty-four per cent (95/113) 
presented with clinical signs of sepsis, and 35% 
(39/113) with features of septic shock. Among the 34 
patients excluded from the per protocol analysis, no 
pathogen was noted in 15 patients. Primary resistant 
pathogens were isolated in seven patients (6%). All the 
79 clinically and bacteriologically evaluable patients 
presented with lower respiratory tract infections. Fifty- 
nine (75%) patients had a mean SAPS I over 10, and 24 
(30%) presented with septic shock. One hundred and 
seventeen pathogens were isolated in the evaluable 
population, and were representative of pathogens 
usually encountered in ICUs, especially in early-onset 
nosocomial pneumonia: Enterobacteriaceae (n=37), 
Staphylococcus aureus (n=25), H. intuenzae (n=16), Pseudo- 
monas aeruginosa (n=12), and Streptococcus pneumoniae 
(n=12). The clinical cure rate was 86% (68/79), while 
the overall proven or presumed pathogen eradication 
rate was 91% (107/117) and 75% for Pseudomonas 
aeruginosa. Cefepime-amikacin combination therapy 
was well tolerated: two patients discontinued treatment 
because of rashes. In this preliminary study, com- 
bination therapy with cefepime (2 g twice-daily) and 
amikacin appeared to be safe and effective for the 
treatment of nosocomial pneumonia in ICU patients. 
Beaucaire et al [12] have performed a multicenter 
(62 ICUs) open-label, randomized prospective study 
comparing cefepime and ceftazidime combined with 
amikacin in VAP in 275 ICU patients (Table 3). One 
hundred and forty-one patients received intravenous 
cefepime (2 g twice-daily) plus intravenous amikacin 
(7.5 mg/kg twice-daily) and 134 patients received 
intravenous ceftazidime (2 g three times a day) plus 
intravenous amikacin (7.5 mg/kg twice-daily). Demo- 
graphic characteristics were similar in the two groups. 
In all patients the bacteriologic diagnosis was assessed 
by protected distal brushing according to Wimberley’s 
technique, with a cut-off point set at lo3 CFU/mL. 
Bacteria associated with VAP were isolated in 105 
(74%) patients treated with cefepime, and 84 (63%) 
patients treated with ceftazidime. Three hundred and 
nineteen causative pathogens were isolated. The mean 
duration of treatment was 11 k 3.3 days in the cefepime 
group (amikacin 7.8 k4.4 days), and 11.4k3.1 days in 
the ceftazidime group (amikacin 7.5 k2.3 days). All 
cases were reviewed in a blind fashion. In the intent- 
to-treat analysis, clinical cure was achieved in 42.8% 
(68/141) of cefepime patients, and in 44.8% (60/134) 
of ceftazidime patients. In the subgroup ofpatients with 
bacteriologically positive pneumonias, the clinical cure 
rate in intent-to-treat analysis was significantly higher 
(56/105; 53.3%) in the cefepime group compared with 
the ceftazidime group (33/84; 39.3%) (pC0 .05) .  In per 
protocol analysis, the clinical cure rate was 67.7% 
(65/96) for the cefepime group and 68.2% (58/85) for 
the ceftazidime group, and no difference was observed 
in the subgroup of patients with bacteriologically 
positive pneumonias (74.3% versus 68.1%). Bacterio- 
logic eradication was reported for 86.5% (64/74) of 
the cefepime patients and 89.3% (42/47) of the 
ceftazidime patients. The clinical safety profile was 
similar in both groups. This study has demonstrated 
that, in the intent-to-treat group, the combination of 
cefepime and amikacin had an efficacy similar to that 
of the standard treatment ceftazidime plus amikacin 
in VAP. In the subpopulation with positive bacterial 
cultures, the combination of cefepime and amikacin 
was superior. 
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Table 3 Comparison of cefepime and ceftazidime in combination with amikacin in the treatment of ventilator-associated 
pneumonia [12] 
~ ~ ~ 
Cefepime (ri = 141) Ceftazidiiiie ( n  = 134) 
Patient characteristics 
Age (years, mean + SD) 
Sex (M/F) 
Admission SAPS I (mean+ SD) 
Enrollment SAPS I (mean+ SD) 
MacCabe score" 
Interval between hospitalization and enrollment (days) (median+ SD) 
Interval between hospitalization and mechanical ventilation (days) 
PaOdFI02 ratio (mean+ SD) 
Lobe impairment (unilateral/bilaterd) 
Digestive decontamination ("A) 
(median+SD) 
Bacteriologic data 
Patients with microbiologically documented infections (n) 
Mono/polymicrobial cultures (n) 
Total number of isolated pathogens (n) 
Gram-positive bacteria 
Staph ylococcur sp. 
Streptococcus pneumoniae 
Streptococcus sp. 
Others 
Gram-negative bacteria 
H .  influenrae 
Enterobacteriaceae 
Pseudornonas aeruginosa 
Others 
Favorable clinical and bacteriologic outcome 
All pneunionias 
Intent-to-treat analysis 
Per-protocol analysis 
Intent-to-treat analysis 
Per-protocol analysis 
Bacteriologically positive pneumonias 
Bacteriologic eradication (proven or presumed) 
56.85 17.8 
99/42 
13.7f4.8 
13.8-ts.3 
88/42/ 11  
15.3-tl9.5 
9.8k13.2 
200.9 f 8 1.8 
75/66 
9 
105 
170 
20 
10 
8 
42/32 
39 (33%) 
I 
76 (66%) 
17 
31 
22 
6 
68/141 (48.2%) 
65/96 (67.7%) 
56/105 (53.3%)' 
64/74 (86.5%) 
55/74 (74.3%) 
56.5-tl7.4 
13.0f1.6 
13.123.7 
83/4O/11 
14.5214.8 
103/31 
8.9210.9 
195.8f88.4 
64/70 
3 
84 
22/25 
149 
24 (29.3%) 
13 
2 
9 
0 
58 (70.7%) 
14 
29 
12 
3 
60/134 (44.8%) 
58/85 (68.2%) 
33/84 (39.3%)' 
32/47 (68.1 %) 
42/47 (89.3%) 
"Non-fatal/ultimately fataVrapidly fatal. 
"MSSA= 16/10 
'p50.05. 
COMPLICATED INTRA-ABDOMINAL INFECTIONS 
Complicated intra-abdominal infections often result in 
significant morbidity and mortality. Effective manage- 
ment of these infections includes early diagnosis, 
surgical procedures and medical supportive care. In 
addition, antibacterial agents are essential to reduce the 
incidence of persistent or recurrent peritonitis, abscess 
formation or local wound infection, and to prevent 
secondary bacteremia or metastatic spread of infection. 
For maximal efficacy, antibiotics should be started 
preoperatively when the diagnosis of intra-abdominal 
infection is suspected. Inadequate empirical antibiotic 
therapy in these patients is one of the strongest 
predictors of a poor clinical outcome [13]. Secondary 
peritonitis is typically polymicrobial, including Entero- 
bacteriaceae, anaerobes like Bacteroides jiagilis and, less 
commonly, Staphylococcus aureus and Pseudornonas sp. 
Successful antibacterial regimens for complicated intra- 
abdominal infections have included a cephalosporin, 
fluoroquinolone, or aminoglycoside in combination 
with an anti-anaerobic agent, or monotherapy with 
a cephamycin, carbapenem, or 0-lactam/p-lactamase 
inhibitor combination. 
The efficacy and safety of intravenous cefepime 
(2 g twice-daily) plus intravenous metronidazole (500 
mg or 7.5 mg/kg every 6 h) compared to intravenous 
imipenem-cilastatin (500 mg/6 h) has been evaluated 
by Barie et a1 [14] in the treatment of complicated 
intra-abdominal infections in 323 adult patients 
(cefepinie-metronidazole group, n=164; imipenem- 
cilastatin group, n=l59) ,  in a prospective randomized 
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double-blind multicenter study. Patients with a pre- 
operative diagnosis of complicated intra-abdominal 
infection or postoperative diagnosis of abscess or peri- 
tonitis were included; in these an operative procedure 
or percutaneous drainage was required for diagnosis and 
management. Surgical management was determined by 
the patients’ surgeons. The clinical efficacy was evaluated 
with a per protocol analysis. Clinical cure was defined 
as elimination of all signs and symptoms relevant to 
the original infection. Treatment failure was defined as 
persistent, increasing or worsening signs and symptoms 
resulting in an antibiotic change, requirement of an 
additional surgical procedure to cure the infection, 
or a wound infection with fever. Of the initial 
isolates, 84% were susceptible to cefepime and 92% to 
imipenem-cilastatin. One hundred and six patients 
were excluded from the per protocol analysis, 
essentially because of the absence of initial isolated 
pathogens (nz53). The patient characteristics were 
equally distributed in the 217 protocol-valid patients, 
95 in the cefepime-metronidazole group and 122 in 
the imipenem-cilastatin group (Table 4). The mean 
APACHE I1 score was in accordance with a relatively 
low severity of infection. Patients treated with 
cefepime-metronidazole were deemed to be clinically 
cured (88%) more frequently than were imipenem- 
cilastatin patients (76%) (p=O.O2). Using multivariate 
analysis to adjust for identified clinical risk factors for 
an adverse outcome, only higher APACHE I1 score and 
prolonged prestudy length of hospitalization appeared 
as significant independent predictors of treatment 
failure. After adjustment for differences between the 
treatment groups in these prognostic factors, there was 
a trend ( ~ ~ 0 . 0 6 )  towards a higher cure rate favoring 
cefepime-metronidazole. Pathogens were eradicated 
in significantly ( ~ ~ 0 . 0 1 )  more patients treated with 
combined cefepinie-metronidazole (89%) than with 
imipenem-cilastatin (76%). The combination cefepime- 
Table 4 Comparison of cefepime plus metronidazole and imipenem-cilastatin in the treatment of complicated intra- 
abdominal infections in per protocol analysis [14] 
Cefepime-metronidazole Imipenem-cilastatin 
(n =95) (n=122) 
Patient characteristics 
Mean age (years) 
Type of surgery (n) 
Open 
Percutaneous 
Mean APACHE I1 score on admission 
Infection diagnosis localization 
Appendicitis (abscess and peritonitis) 
Other peritonitis 
Other abscess 
Bacteriologic data 
Total number of isolated pathogens (n) 
Mean number of pathogendpatients 
Gram-positive aerobes 
stap~yrococ~~s sp. 
Enterococcus sp. 
Streptococcus sp. 
Others 
Gram-negative aerobes 
Enterobacteriaceae 
Pseudomonas sp. 
Others 
Anaerobes 
Fungi 
49.3 
83 
12 
7.8a 
31 
27 
37 
290 
3.1 
85 (29%) 
23 
16 
42 
4 
73 
12 
12 
9 
97 (33%) 
99 (34%) 
51.5 
99 
23 
9.3 
40 
32 
50 
391 
124 (32%) 
3.2 
27 
20 
69 
20 
29 
19 
18 
13 
146 (37%) 
108 (28%) 
Mean duration of antibiotic treatment (days) 8.8 9.4 
Favorable outcome 
Clinical cure 84/95 (88%) 93/122 (76%) 
Bacteriologic eradication 85/95 (89%)‘ 93/122 (76%) 
”p=0.04. 
“=0.02. 
‘p=0.01. 
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metronidazole appears to be safe and effective therapy 
for patients with severe intra-abdominal infections. 
FEBRILE NEUTROPENIC PATIENTS 
The use of antibiotics is always the cornerstone of 
therapy for febrile patients with cancer and severe, 
treatment-induced neutropenia [ 15,161. Empirical 
antimicrobial treatment strategies for these febrile 
episodes include combination therapy with a broad- 
spectrum antipseudomonal penicillin and an amino- 
glycoside or a quinolone, or, alternatively, mono- 
therapy with an antipseudomonal cephalosporin or 
carbapenem. The combination of a p-lactam antibiotic 
with an aminoglycoside provides broad-spectrum cover, 
particularly for Gram-negative pathogens. The intro- 
duction of extended-spectrum cephalosporins could 
enhance this cover. In Europe, ceftazidime combined 
with anlikacin is often used as the first-line regimen for 
fever in persistently and severely neutropenic patients. 
Because of the increasing incidence of infections due 
to Gram-positive cocci in these patients, glycopeptides 
are frequently added to the therapeutic regimen. These 
antibiotics are given because ceftazidime exhibits poor 
efficacy against methicillin-resistant staphylococci and 
many streptococci. Cefepime has activity similar to that 
of ceftazidime against Pseudomonas aeruginosa and equal 
to or better than that of ceftazidime against Entero- 
bacteriaceae. It also has the advantage of being active 
against Gram-positive cocci, as do other cephalosporins 
such as cefotaxime [1,6,17]. Considering the spectrum 
of pathogens encountered in febrile neutropenic 
patients, cefepime used in combination or alone should 
be a useful agent for these patients [2]. 
Cordonnier et a1 [I81 have conducted a random- 
ized open multicenter study comparing the efficacy 
Table 5 Comparison of cefepime-amikacin and ceftazidime-amikacin in the treatment of febrile neutropenic patients with 
hematologic malignancies in per protocol analysis 11 81 
Cefepime-amikacin Ceftazidinie-amikacin 
(n=212) ( n  = 107) 
Patient characteristics 
Mean age (+SD; years) 
Acute myeloid leukemia/mnyelodysplasia (n) 
Lymphoproliferative disease (n) 
Acute lymphoblastic leukemia (n) 
Others (ti) 
PMN count S100/mm3 (n )  
PMN count I10/mm3 (n) 
Median number of PMNs/mm’ on enrollment 
Mean neutropenia duration (f SD; days) 
Bacteriologic data 
Microbiologically documented infection 
Clinically documented infection 
Fever of unknown origin 
Number of isolates (ti) 
Gram-positive cocci 
Bactereinia 
Methiclllin-resistant Staphy~ococcus p. 
Methicillin-susceptible Staphylococcus sp. 
Streptococcus sp. 
Enterococcus sp. 
Others 
Gram-negative bacilli 
Enterobacteriaceae 
Psrudomonas sp. 
Others 
Primary resistant pathogens (n)  
44514 45514 
98 
75 
24 
15 
152 
69 
95 
27?16a 
69 (33%) 
63 (91%) 
123 (58%) 
77 
SO (65%) 
13 
13 
18 
3 
3 
27 (35%) 
19 
5 
3 
20 (9%) 
29 (25%) 
50 
39 
10 
8 
71 
32 
100 
23+15a 
30 (28%) 
25 (83%) 
8 (7%) 
69 (64%) 
37 
28 (76%) 
8 
9 
6 
3 
2 
9 (24%) 
7 
0 
2 
34 (30%) 
Mean duration of antibiotic treatment (days) 8.8 9.4 
Favorable clinical outcome 
Clinical cure (initial treatment) 57/212 (27%) 23/107 (21%) 
32/74 (43%) Clinical cure (glycopeptides added) 701136 (51%) 
55/107 (51%) Overall clinical cure 127/212 (60%) 
’p=0.07. 
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and safety of two antibiotic regimens (cefepime 2 g 
twice-daily plus amikacin 7.5 mg/kg twice-daily versus 
ceftazidime 2 g three times a day plus amikacin 7.5 
mg/kg twice-daily) as first-line therapy for fever in 
patients with hematologic malignancies and profound 
and prolonged neutropenia. Glycopeptide could be 
added in several previously defined situations. Three 
hundred and fifty-three patients were randomized 
according to a 2: 1 (cefepime/ceftazidime) ratio (Table 
5). Two hundred and twelve patients in the cefepime 
group and 107 in the ceftazidime group (90% of all 
patients) were evaluable for efficacy in a per protocol 
analysis. Twenty five per cent of the isolates (29/114) 
had primary resistance to cefepime versus 30% (34/114) 
to ceftazidime. After exclusion of methicillin-resistant 
Staphylococcus sp. and Enterococcus sp. that are always 
resistant to the third-generation cephalosporins, the 
rate of primary resistance to Gram-positive cocci was 
significantly higher in the ceftazidime group than in 
the cefepime group (34/78 versus 27/78; p=0.029). 
The polymorphonuclear neutrophil (PMN) count was 
5 100/mm3 on enrollment for 70% of the patients. The 
mean duration of neutropenia was 26 days, slightly 
longer in the cefepime group. The distribution of the 
patients according to bacteriologically documented 
infections, clinically documented infections and fever 
of unknown origin was similar between the two 
groups. The efficacy in both study arms was com- 
parable, although a trend in favor of cefepime was 
noted in terms of therapeutic success (response rate, 
27% versus 21% for the ceftazidime group). The overall 
response rate on the fourth day after the end of 
treatment and after glycopeptides were added to the 
initial regimens was 60% for the cefepime group and 
51% for the ceftazidime group. The bacterial eradication 
rates were 81% versus 76%, respectively, and the rates 
of new bacterial infections 14% and 18%, respectively. 
The authors concluded that cefepime-amikacin was at 
least as effective as the reference regimen ceftazidime- 
amikacin in high-risk, febrile neutropenic patients. 
Another open-label randomized trial was con- 
ducted by Yamarnura et al [19] comparing the efficacy 
and safety of intravenous cefepime (2 g three times a 
day) versus intravenous piperacillin (3 g/4 h) plus 
intravenous gentamicin (1.5 mg/8 h) for the treatment 
of febrile episodes in adult neutropenic patients with 
underlying malignancy. One hundred and eleven 
patients were enrolled and a per protocol analysis was 
performed in 99 patients. The distribution of the 
patients according to their characteristics was similar 
between the two groups (Table 6). Vancomycin was 
added to the initial treatment regimens in 13 patients 
in the cefepime group, and in 14 patients in the 
piperacillin-gentamicin group. At the 72-h evaluation, 
cefepime and piperacillin-gentamicin produced com- 
parable clinical response rates (78%). They also produced 
comparable response rates in microbiologically docu- 
mented (78% versus 71%), clinically documented 
Table 6 Comparison of cefepime and piperacihn-gentamicin in the treatment of febrile neutropenic patients with 
hematologic malignancies and cancer in per protocol analysis [19] 
Cefepime Piperacillin-gentamicin 
(n=50) (n=49) 
Patient characteristics 
Hematologic malignancy (n) 
Solid tumors (n)  
Mean number of PMNs/mm3 on enrollment 
Mean neutropenia duration (5 SD; days) 
Microbiologically documented infection (n)  
Clinically documented infection (n) 
Fever of unknown origin (n) 
Bacteriologic data 
Number of isolates (n) 
Gram-positive cocci (n)  
Gram-negative bacilli (n) 
37 
13 
2525285 
9.0k7.7 
21 (42%) 
24 (48%) 
5 (10%) 
17 
10 
7 
27 
22 
2445281 
9.627.5 
27 (55%) 
20 (41%) 
2 (4%) 
24 
9 
15 
Favorable outcome 
Overall clinical cure 39 (78%) 38 (78%) 
Microbiologically documented infection 15/21 (71%) 21/27 (78%) 
Fever of unknown origin 19/24 (79%) 15/20 (75%) 
Clinically documented infection 515 (100%) 2/2 (100%) 
Gram-positive cocci 7/10 (70%) 4/9 (44%) 
Overall bacteriologic eradication 12 (71%) 19 (79%) 
Gram-negative bacilli 5/7 (71%) 15/15 (100%) 
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Table 7 Comparison of cefepime and comparators in the treatment of febrile episodes in neutropenic cancer patients [20] 
Cefepime 
(n=109) 
Comparators 
(n=107) 
Episode characteristics 
Hematoiogic malignancy (n) 
Solid tumors (n) 
<SO0 PMNs/mm3 (n) 
< 100 PMNs/mm3 (n) 
Microbiologically documented infection (n) 
Clinically documented infection (n) 
Fever of unknown origin (n)  
Primary rewtant pathogens 
Favorable outcome 
Afebrile ( 5 4  days) 
Study therapy alone 
With modification 
End of the study 
Survived (230  days after therapy) 
Overall bacteriologic eradication 
80 
29 
68 
53 
47 (43%) 
8 (7%) 
54 (50%) 
9/89 (10%) 
60/103 (58%) 
38/45 (84%) 
22/58 (38%) 
74/100 (74%) 
98/100 (98%) 
48/50 (96%) 
75 
32 
71 
51 
44 (41%) 
56 (52%) 
7 (7%) 
8/38 (21%)" 
9/48 (19%)h 
63/105 (60%) 
33/42 (79%) 
30/63 (48%) 
771101 (76%) 
98/107 (92%) 
50/50 (100%) 
'Ceftazidime 
Piperacihn. 
(100% versus 100%) and possible (75% versus 79%) 
infection. They also achieved comparable microbio- 
logical eradication of Gram-negative (1 00% versus 
71%) and Gram-positive (44% versus 70%) organisms. 
There were no statistically significant differences in the 
rates of superinfection between the two groups. 
However, more superinfections with fungi were noted 
in the piperacillin-gentamicin group. In this study, 
cefepime was demonstrated to be an effective and safe 
treatment for febrile episodes in neutropenic patients 
with malignancies, and its lack of nephrotoxicity 
compared to piperacillin-gentamicin was noteworthy. 
Cefepime appears to be a candidate for monotherapy 
in febrile neutropenic cancer patients. 
Finally, Ramphal et a1 [20] have published the 
results of two randomized, open, multicenter trials 
comparing the efficacy of intravenous cefepime (2 g 
three times a day) to a comparator regimen of either 
intravenous cefiazidime (2 g three times a day) or 
intravenous piperacillin plus gentamicin (3 g/4 h + 1.5 
mg/8 h) as first-line therapy in 193 febrile, intravenous 
neutropenic cancer patients. When indicated, vanco- 
mycin was added to the regimen. One hundred and 
nine febrile episodes were treated with cefepime and 
107 episodes with the comparator regimens (Table 7). 
Neutropenia (5 500 PMNs/mm3) persisted for more 
than 10 days in more than 40% of episodes, and severe 
neutropenia (5 100 PMNs/mm') was present in more 
than 25% of episodes. More than 40% of the total 
number of episodes were documented bacterial in- 
fections. These characteristics did not differ among 
treatment groups. Duration of therapy was similar in 
both groups (median: cefepime, 9 days; comparators, 
11 days). In more than 40% of episodes, patients 
received study therapy without addition of other 
antibacterials. Vancomycin was added in almost half 
of all episodes (cefepime, 45%; comparators, 53%). 
Clinical and bacteriologic results were similar in 
cefepime and comparator groups. Patients became 
afebrile by the fourth day of study therapy in approxi- 
mately 60% of episodes. In approximately 75% of the 
episodes, patients had a satisfactory response at  the end 
of therapy. Following approximately 90% of episodes, 
patients survived for more than 30 days. Eradication 
rates were similar for all pathogens for cefepime and 
comparator agents. There were similar numbers of 
superinfecting organisms in each treatment group, 
mostly involving Gram-positive organisms. These results 
suggested that initial empirical cefepime monotherapy 
is comparable to standard therapies. 
CONCLUSION 
This review of the clinical activity of cefepime in the 
treatment of various, severe infections illustrates that 
cefepime, alone or combined with aminoglycosides, is 
as effective as standard comparators, especially in ICU 
patients with nosocomial pneumonia and in febrile 
neutropenic patients, or more effective than com- 
parators in complicated intra-abdominal infections, 
when associated with metronidazole. Also, the primary 
resistance, when evaluable, is less frequent in the 
cefepime group, especially in Gram-positive cocci. This 
helps explain the good clinical results of cefepime when 
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used empirically, as in bacteriologically documented 
nosocomial pneumonia. 
Cefepime is an appropriate candidate for first- 
choice antibiotic therapy in the empirical treatment of 
severe infections. 
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